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Abstract 
Background: Sentinel lymph node biopsy is the gold standard surgical technique for axillary staging in patients with 
clinically node-negative. However, it is still uncertain what is the optimal number of sentinel lymph nodes (SLNs) to 
be removed to reduce the false-negative rate. The aim of this study was to investigate whether patients with a single 
negative SLN have a worse prognosis than those with two or more negative SLNs.
Methods: A retrospective review was conducted on a large series of SLN-negative breast cancer patients. Survival 
outcomes and regional recurrence rate were evaluated according to the number of removed SLNs. Secondly, the 
contribution of different adjuvant therapies on disease-free survival was explored. Statistical analysis included the chi-
square, Wilcoxon–Mann–Whitney test, and Kaplan–Meier survival analysis.
Results: A total of 1080 patients were included in the study. A first group consisted of 328 patients in whom a single 
SLN was retrieved, and a second group consisted of 752 patients in whom two or more SLNs were retrieved. There 
was no relevant difference in median DFS (64.9 vs 41.4) for SLN = 1 vs SLN > 1 groups (HR 0.76, CI 95% 0.39–1.46; p 
= 0.38). A statistically significant difference in mDFS was showed only for HT-treated patients who were SLN = 1 if 
compared to SLN > 1 (100.6 months versus 35.3 months).
Conclusions: There is likely a relationship between the number of resected SNL and mDFS. Our results, however, 
showed no relevant difference in median DFS for SLN = 1 vs SLN > 1 group, except for a subset of the patients treated 
with hormone therapy.
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Background
For two decades now, sentinel lymph node biopsy (SLNB) 
has replaced axillary lymph node dissection (ALND) 
as the standard minimally invasive procedure for axil-
lary staging in clinically node-negative (cN0) breast 
cancer. Some important clinical trials demonstrated 
that SLNB alone is equivalent to ALND in axillary stag-
ing, with fewer associate postoperative morbidity out-
comes. Moreover, SLNB alone found equivalent efficacy 
to upfront ALND in disease-free survival (DFS), overall 
survival (OS), and regional recurrences (RR) [1, 2].
However, despite many studies subsequently confirmed 
these findings [3], some concerns remain regarding the 
false-negative rate (FNR) associated with the use of SLNB 
alone. Weaver et  al. [4] reported a 15.9% incidence of 
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occult metastases after further examination of initially 
pathologically negative sentinel lymph nodes (SLNs). In 
this study, patients with occult metastasis had worse OS, 
DFS, and distant DFS than those without occult nodal 
metastasis. Moreover, some other authors confirmed an 
increase of false-negative rates if a single SLN has been 
removed [5, 6]. Ban et  al. [7] reported a FNR of 26.6% 
when a single SLN was retrieved, compared to 0% for 
four or more nodes, suggesting that four SLNs may rep-
resent an optimal threshold. The count did not include 
the parasentinel lymph nodes. Other authors conclude 
that at least two SLNs may be removed to reduce the 
FNR and to improve the outcomes in terms of OS, DFS, 
and RR [8, 9].
Based on the aforementioned studies, it could be con-
cluded that missed positive nodes may lead to an under-
staging and thus to undertreatment of those SLN patients 
with occult metastasis within the SLNB. It also indicates 
a decreased negative predictive value for SLNB in set-
tings where only a single SLN is detected. However, none 
of these studies investigated the outcomes in terms of 
OS, DFS, and local and distant recurrences for patients 
with a single SLN comparing them with those of patients 
with two or more SLNs assessed.
Based on these assumptions, the main purpose of our 
study was to investigate whether patients in whom only 
one lymph node was found during SLNB have a worse 
prognosis than patients in whom two or more sentinel 
lymph nodes were found and examined.
Materials and methods
After approval by the Institutional review board at Uni-
versity Hospital “AOUP Paolo Giaccone” of Palermo, 
we collected and retrospectively analyzed the medical 
records of a large series of patients with primary cN0 
invasive breast cancer observed at our Institution from 
January 2013 to September 2019. Each patient under-
went synchronous excision of the breast cancer either by 
conservative surgery or by total mastectomy and SLNB. 
Whole breast radiation therapy and systemic adjuvant 
therapies were administered according to the interna-
tional guidelines.
Eligibility criteria were a preoperative diagnosis of pri-
mary invasive breast cancer defined through fine nee-
dle aspiration cytology and/or by percutaneous needle 
core biopsy, clinically negative ipsilateral axillary lymph 
nodes (cN0), and pathologic negative axillary lymph 
nodes (pN0) at SLNB. Exclusion criteria from the study 
were clinically positive ipsilateral axillary lymph nodes, 
a previous neoadjuvant therapy, pathologic positive axil-
lary lymph nodes at SLNB, inflammatory breast cancer, 
locally recurrent breast cancer, metastatic disease at the 
diagnosis, and lack of follow-up data.
SLN was detected using the identification technique 
with radiotracer and, if necessary, the use of the vital dye, 
as described in our previous studies [10–13]. Briefly, all 
patients underwent a preoperative lymphoscintigraphy 
employing a subdermal periareolar injection of 99Tc-
labeled human albumin colloid (10–12 MBq di Tc-99m in 
0.2 ml of albumin colloid), 18–24 h before surgery. For 
intraoperative identification of the SLN, a radio-guided 
surgical probe was used to identify the area with the 
greatest radioactive intensity. Limited to the cases were 
the radio-guided surgical probe detected a weak radi-
otracer signal, a subareolar injection of 0.5–0.8 ml of vital 
stain about 10–15 min before surgery was performed.
All hot and/or blue lymph nodes were removed and 
submitted immediately for intraoperative assessment by 
frozen section (FS). Intraoperative examination was car-
ried on two 4-μm frozen sections stained with hema-
toxylin and eosin (H&E). All the remaining tissue was 
formalin-fixed, paraffin-embedded, and entirely sec-
tioned at 100-micron intervals for the definitive histo-
pathological examination. Finally, any enlarged palpable 
or suspect lymph nodes were removed and sent for defin-
itive histopathological examination to reduce the risk 
of a false negative at SLNB due to abnormal lymphatic 
drainage.
All patients with SLN macro-metastasis at the frozen 
section underwent immediate completion ALND. In the 
cases of SLN negative at frozen section but positive for 
macrometastases at definitive histopathological exami-
nation, patients underwent a delayed completion ALND. 
No completion ALND was performed in women with 
metastasis-free SLN, ITC, and patients with SLN micro-
metastases, either at intraoperative or at final histopatho-
logical examination. Several studies have actually shown 
that in patients where SLN is positive for micrometas-
tasis, ALND can be safely omitted because it does not 
improve survival [14–17].
The primary endpoint was to evaluate the median 
disease-free survival (mDFS) according to the number 
of nodes collected after SLNB (1 or more than 1). Sec-
ondly, we would explore the contribution of different 
adjuvant therapies: hormone therapy (HT), hormone 
therapy plus chemotherapy (HT+CT), or chemother-
apy (CT) on mDFS. Steroid or non-steroidal aromatase 
inhibitors have been used in postmenopausal patients, 
while tamoxifen plus LH-RH analogs in premenopausal 
patients. Furthermore, we would evaluate the regional 
recurrences (RRs) and the distant metastases (DM) rates 
according to SNLB (1 or more than 1). RRs include both 
local intramammary and axillary recurrences.
We analyzed all patients according to the age at the 
diagnosis, type of surgery, SLN status, tumor size, his-
tological type, estrogens (ER) and progesterone (PR) 
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receptor status, and human epidermal growth factor 
receptors 2 (HER2) status. Tumors with ≥1% positive 
nuclear-stained cells were considered positive for ER 
and PR expression, and those with an immunohisto-
chemical score +3 according to the ASCO/CAP 2018 
criteria [18] were considered positive for HER2. More-
over, radiation therapy and systemic adjuvant therapy 
administration were evaluated as co-variables to deter-
mine whether in each of these patients the tumor or 
associated treatment was predictive factors for recur-
rence and/or death.
The patients included in the study based on the 
above-mentioned criteria were divided into two groups 
according to the number of negative SLNs found intra-
operatively. The first group included patients in whom 
SLNB has found a single negative SLN, while the sec-
ond group included all patients with two or more nega-
tive SLNs. The distributions of patients in groups with 
respect to baseline demographic and clinical charac-
teristics will be compared through the chi-square test 
for heterogeneity and the Wilcoxon–Mann–Whitney 
test for categorical and continuous variables, respec-
tively. Survival (DFS and OS) analysis will be per-
formed using the Kaplan–Meier method, providing 
median and p values, with the use of the log-rank test 
for comparisons. Outcomes with a p value < 0.05 will 
use as a threshold for statistical significance. All the 
statistical analyses will be performed using SPSS sta-
tistics software, version 20 (IBM, Armonk, NY, USA) 
[19].
Results
In the period between January 2013 and September 2019, 
a total of 1901 women with primary cN0 invasive breast 
cancer underwent a sentinel lymph node biopsy at our 
Surgical Oncology Unit, according to the aforementioned 
inclusion criteria.
At intraoperative FS examination of the SLNs, mac-
rometastases were found in 281 patients (14.8%) and 
micrometastases in 18 patients (0.9%), whereas 1602 
patients (84.3%) had negative SLN. However, SLN metas-
tases were found in 181 cases (9.5%) at the definitive 
histopathological examination, increasing the number 
of patients with positive SLNs to a total of 480 (25.2%). 
These patients were excluded from the study. Therefore, 
1422 patients with a confirmed diagnosis of negative 
SLNs were considered eligible for the study. However, a 
further 342 of these were excluded from the study due to 
missing data.
Finally, a total of 1080 patients were included in the 
study (Fig. 1). The first group consisted of 328 patients in 
whom a single SLN was retrieved, and the second group 
consisted of 752 patients in whom two or more SLNs 
were retrieved.
The average number of negative SLN removed in this 
group was 2.1 (range 1–10 lymph nodes). The median 
follow-up ranged from 6 to 72 months with a median of 
44.5 months.
The demographic and clinical-pathological characteris-
tics of the tumor are summarized in Table 1.
The results of our study first confirm the prognos-
tic role of T stage on disease recurrence/relapse (T1 = 
1.8%; T2 2.4%, T3 = 10.5% - chi-square 12.9; p = 0.002) 
Fig. 1 Flow chart of patients with negative SLNs. SLNs sentinel lymph nodes, FS frozen section, DHE definitive histopathological examination
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regardless of the number of removed SLNs. No statisti-
cally significant differences were provided in SNL = 
1 and SNL > 1 cohort according to different relevant 
parameters (age, tumor size, grading, histology, recep-
tor status). Furthermore, no difference was also under-
lined in cancer treatments and in particular, surgery 
(total mastectomy or quadrantectomy), radiant therapy, 
and systemic therapy (HT, HT+CT, or CT). Of note, the 
large majority of our population received conservatory 
strategy except for rare cases associated with very large, 
multicenter, or aggressive tumor features (Table 2). In all 
patients treated with conservative surgery, local radical-
ity was always confirmed by “no ink on tumor” resection 
margins.
In our enrolled population, a total of 17 RRs were 
registered during the follow-up period. In particular, 6 
RRs were in the SLN = 1 cohort and 11 RRs in SLN > 
1 cohort respectively. Our series reported a lower per-
centage of distant relapses around 0.8% (0.6% visceral; 
0.2% bone). Four DM were in the SLN = 1 group while 7 
DM were in the SLN >1 group. Table 3 underlines tumor 
recurrences, local and distant, in both patient groups. 
Through a detailed comparison between the local and 
remote recurrence rates, we notice a greater number of 
local recurrences in the group with two or more negative 
sentinel lymph nodes intraoperatively, and, conversely, 
more remote recurrences in the group with a single nega-
tive sentinel lymph node. It is not, however, a statistically 
significant association.
Besides, overall population mDFS was 40.4 months. 
Our results showed no relevant difference in median DFS 
(64.9 vs 41.4) for SLN = 1 vs SLN > 1 group (HR 0.76, CI 
95% 0.39–1.46; p = 0.38) (Fig. 2).
We planned a subgroup analysis according to different 
systemic therapy. In our early breast cancer population, 
a statistically significant difference in mDFS was showed 
for HT-treated patients who were SLN = 1 if compared 
to SLN > 1 (100.6 months versus 35.3 months). No rel-
evant differences were retrieved in HT + CT (132.8 vs 
154.9) or only CT (16.1 vs 26.1) subgroups (Fig. 3).
Discussion
SLNB remains to this day the standard technique for 
staging the axillary cavity in patients with early-stage 
breast cancer [20–23]. It should be noted, despite a 
good lymph node collection, patients are still exposed 
to the risk of local or distant recurrence. Previous 







n. % n. %
Age (years)
 <40 12 3.6% 20 2.7% 0.91
 40–49 56 17% 112 15%
 50–69 216 66% 524 69.6%
 >70 44 13.4% 96 12.7%
Tumor size
 T1(<20mm) 216 65.8% 536 71% 0.45
 T2 or greater 112 32.9% 216 29%
Grading
 I 96 29.3% 196 26% 0.95
 II 156 47.6% 384 51%
 III 52 15.8% 116 15.5%
 Indeterminate 24 7.3% 56 7.5%
Histology
 Invasive ductal 240 73.2% 568 75.5% 0.91
 Invasive lobular 36 10.9% 72 9.6%
 Others 52 15.9% 112 14.9%
Receptor status
 ER+ 294 89.6% 660 87.7% 0.79
 PR+ 270 82.2% 605 80.5%
 HER2/neu+ 107 32.7% 240 31.9%
 ER+, PR+, HER2+ 75 22.8% 168 22.4%
 Triple negative 13 4.1% 49 6.5%






n. % n. %
Surgery 0.06
 Quadrantectomy 328 100% 736 7.9%
 Total mastectomy ___ 16 2.1%
Radiant therapy 328 100% 736 97.9% 0.61
Systemic therapy 0.99
 Chemotherapy 20 6% 71 9.5%
 Hormone therapy 244 74.3% 551 73.3%
 Combination therapy 64 19.5% 130 17.2%
Table 3 Regional and distant tumor recurrences





n. % n. %
Total 10 3.0% 18 2.4% 0.98
Free-disease patients 316 97.0% 724 97.6%
Recurrence sites
 Local 6 1.8% 11 1.5% 0.35
 Distant 4 1.2% 7 0.9% 0.17
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experiences also suggest that certain characteristics 
such as multifocal disease or parameter T can modify 
both the risk of lymph node involvement of the axil-
lar and the risk of disease recurrence (both local and 
distant) [24]. The results of our study first confirm 
that the T parameter influences the appearance of RRs 
(T1 = 1.8%; T2 2.4%, T3 = 10.5% - chi-square 12.9; p 
= 0.002). Specifically, the study that enrolled a large 
cohort of patients showed that there is probably no 
direct relationship between the number of lymph nodes 
removed during SLNB and better DFS. In this regard, 
previous studies have shown that the risk of lymph 
Fig. 2 Kaplan–Meier showing median disease-free survival results according to sentinel lymph nodes
Fig. 3 Kaplan–Meier showing median disease-free survival results according to sentinel lymph nodes and different treatment options
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node recurrence after negative SLNB is around 0–1.5% 
after a follow-up of at least 2 years [25].
Adjuvant therapies are among the factors that can 
influence the incidence of regional recurrences in 
patients with negative SLN [26–30]. Some randomized 
clinical trials have shown a positive effect of adjuvant 
therapies on the risk of loco-regional recurrence [31, 
32]. Van Maaren et al. observed a lower risk or regional 
recurrence after breast-conserving surgery than after 
total mastectomy, suggesting a positive effect of radio-
therapy on the regional recurrence rate [33]. In our study, 
a statistically significant difference in mDFS was showed 
for HT-treated patients who were SLN = 1 if compared 
to SLN > 1 (100.6 months versus 35.3 months). Instead, 
no relevant differences were retrieved in HT + CT (132.8 
vs 154.9) or only CT (16.1 vs 26.1) subgroups.
In our experience, the local recurrence rate (breast and 
lymph nodes) in patients with negative sentinel lymph 
nodes was overall 1.8% (breast 0.3%; lymph nodes 1.5%) 
at a median follow-up of 44.2 months. Our results can 
therefore be considered in line with what is reported in 
the literature. These interesting results were obtained 
probably also thanks to the great care in limiting margins 
during conservative surgery. Besides, there was no signif-
icant difference between the relapse rate in those patients 
who had only one lymph node removed and those who 
had removed >1 node (2.11% vs 1.61%). Similar results 
were obtained for distant relapses. Other experiences 
have suggested that the distant relapse rate in this patient 
setting is around 3.5% [14]. Our series reported a lower 
percentage of distant relapses around 0.8% (0.6% visceral; 
0.2% bone). A probable explanation for this discrepancy 
could be linked to the higher proportion of patients 
with favorable prognostic characteristics (ER +, PR +, 
HER2−, ki67 <20%) undergoing treatment with hormone 
therapy who developed indolent metastases mainly in the 
bone.
Limits of our study include the retrospective design 
and the presence of missing data that influence patient 
exclusion from the analysis (17%) mostly due to incom-
plete non-electronic medical records. Furthermore, it is 
a single-center experience, in which the outcome of the 
SLN > 1 group could be influenced by the progressive 
time-dependent improvement of the surgical technique, 
limiting the gap. Besides, to evaluate procedure cost-
effectiveness, no available data from our clinical were 
useful to compare the incidence of peri- or postoperative 
adverse events incidence between groups.
In conclusion, our results confirm the low rate of breast 
cancer recurrence after conservative surgery if the pri-
mary tumor is completely excised with care for negative 
margins. Also, SNLB is to be considered as the standard 
of care for cN0 breast cancer patients even though there 
is likely a relationship between the number of resected 
SNL and mDFS. Our results showed no relevant differ-
ence in median DFS (64.9 vs 41.4) for SLN = 1 vs SLN 
> 1 group (HR 0.76, CI 95% 0.39–1.46; p = 0.38), except 
for a subset of the patients treated with hormone therapy. 
Further studies also involving molecular characteristics 
are needed.
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